Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
Muñoz Couselo, Eva (Hospital Universitari Vall d'Hebron)
Pérez-García, José (Hospital Universitari Vall d'Hebron)
Cortés, Javier (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Date:	2011
Abstract:	Metastatic breast cancer (MBC) remains an incurable disease, with the goals of care aimed at maximizing the patient's duration and quality of life. Treatment options for MBC have become more efficacious and numerous. In addition to endocrine and chemotherapy agents, a number of targeted agents, including trastuzumab and bevacizumab, have further enhanced the landscape of therapeutic options. Eribulin mesylate (E7389) is a nontaxane microtubule dynamics inhibitor, and a structurally simplified synthetic analog of the natural marine product, halichondrin B, with a novel mechanism of action that has shown antitumor activity in pretreated MBC. Eribulin has shown a manageable tolerability profile in Phase I-II clinical trials and an improvement in overall survival compared with treatment of physician's choice, without relevant toxicities in a recently published Phase III trial. This review will focus on eribulin as a new active agent for MBC and its role in the management of breast disease.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Eribulin mesylate ; Halichondrin B ; Metastatic breast cancer ; Tubulin-targeted agents
Published in:	OncoTargets and therapy, Vol. 4 (november 2011) , p. 185-192, ISSN 1178-6930

DOI: 10.2147/OTT.S16392
PMID: 22162924

8 p, 215.1 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles